Search results
Results from the WOW.Com Content Network
Ketamine-assisted psychotherapy (KAP) is the use of prescribed doses of ketamine as an adjunct to psychotherapy sessions. KAP shows significant potential in treating mental disorders such as treatment-resistant depression (TRD), anxiety , obsessive–compulsive disorders (OCD), post-traumatic stress disorders (PTSD), and other conditions. [ 1 ]
Evidence is growing for the use of atypical psychedelics such as ketamine for treating depression in terminally ill patients, with repeated IV administration having the most therapeutic effect. [64] These studies did not have any patients experience any serious adverse effects; however, ketamine-induced ulcerative cystitis is a concern for ...
The more active enantiomer, esketamine (S-ketamine), is also available for medical use under the brand name Ketanest S, [136] while the less active enantiomer, arketamine (R-ketamine), has never been marketed as an enantiopure drug for clinical use. While S-ketamine is more effective as an analgesic and anesthetic through NMDA receptor ...
The Boise Ketamine Clinic was the first ketamine clinic in Idaho and among the first 10 or 11 ketamine clinics to open across the country, Rice said. Since then, more clinics have opened in Idaho.
Ketamine was FDA-approved in 1970 as an anesthetic and has many more studies and 50-plus years of safety and efficacy surrounding its use in general. At Ketamine Clinics Los Angeles, we have ...
Esketamine, sold under the brand names Spravato (for depression) and Ketanest (for anesthesia) among others, [10] [12] is the S(+) enantiomer of ketamine. [5] [13] It is a dissociative hallucinogen drug used as a general anesthetic and as an antidepressant for treatment of depression.
NMDA receptor antagonists induce a state called dissociative anesthesia, marked by catalepsy, amnesia, and analgesia. [1] Ketamine is a favored anesthetic for emergency patients with unknown medical history and in the treatment of burn victims because it depresses breathing and circulation less than other anesthetics.
In October 2023, the FDA warned about using the substance to treat psychiatric disorders in non-injectable forms, noting that safety concerns that may be associated with ketamine usage include ...